Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Boston Scientific starts Synergy study: Enrollment has begun in the randomized, single-blind, non-inferiority EVOLVE clinical trial comparing the firm's fourth-generation Synergy bioabsorbable polymer/everolimus-eluting stent to its Promus Element everolimus-eluting stent in patients with single de novo native coronary artery lesions, Boston Scientific announces Aug. 3. The primary clinical endpoint is target lesion failure at 30 days, a composite measure of cardiac death, myocardial infarction and target lesion revascularization, and the primary angiographic endpoint is in-stent late loss at six months. Synergy is designed to offer restenosis reduction with faster and more complete vessel healing after stent implantation, Boston Scientific says. EVOLVE will be used to support a CE mark for Synergy, which was previously called Evolution. The firm said recently it is anticipating a mid-2012 U.S. launch of Promus Element, already available in Europe
Advertisement

Related Content

AHRQ Maps Out Data Needs For Percutaneous Heart Valves
AHRQ Maps Out Data Needs For Percutaneous Heart Valves

Topics

Advertisement
UsernamePublicRestriction

Register

MT029239

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel